Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression
about
Long non-coding RNAs in anti-cancer drug resistanceA phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.MicroRNA profile in very young women with breast cancerChemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (-)-Gossypol (AT-101)Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches.The BH3-mimetic gossypol and noncytotoxic doses of valproic acid induce apoptosis by suppressing cyclin-A2/Akt/FOXO3a signaling.A novel Osmium-based compound targets the mitochondria and triggers ROS-dependent apoptosis in colon carcinomaAn outline of main factors of drug resistance influencing cancer therapy.MicroRNA-mediated drug resistance in ovarian cancer.Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.Curcumin reduces mitomycin C resistance in breast cancer stem cells by regulating Bcl-2 family-mediated apoptosis.The aldehyde group of gossypol induces mitochondrial apoptosis via ROS-SIRT1-p53-PUMA pathway in male germline stem cell.Gossypol toxicity from cottonseed products.Identification of glucuronidation and biliary excretion as the main mechanisms for gossypol clearance: in vivo and in vitro evidence
P2860
Q28072366-36FF134F-1E80-43ED-8BEA-55193B746D82Q33415855-71377568-5367-4943-A397-D81DB76755C9Q34468715-3F0527C3-0C3A-432D-925B-017CA05E001AQ35605849-78C49959-7B81-45F2-A144-EE4ED1441EF5Q35743521-4DF7BA0D-71C6-400E-A5E0-4835ECE49463Q36589753-98B8857D-BF2E-4B5C-B55B-4025616DA50CQ36629469-8B3D120F-0A59-45C5-8D9D-8FA400FFC12CQ36973759-4657A447-A8CA-429C-B21E-EBE985F14498Q38933079-669D6633-2BC3-45E7-92EC-B840264FCCF3Q39382756-FDCB834A-4D83-4ECE-8C75-CFCE45B65AF5Q40699159-584283DE-A789-4962-BEED-DBE3241BF41BQ41670781-7973568F-3699-43DB-BF9F-3E9F8D5E2B70Q46238874-D6FD156E-B578-4F5B-A7AE-6B61B2E9F4D2Q51136239-4805F292-2973-4FE2-9681-643AB1C22029Q57151091-360375AD-7C89-4DB1-9CB6-F2011475C5C3
P2860
Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Combination therapy with gossy ...... lls with high BCL-2 expression
@ast
Combination therapy with gossy ...... lls with high BCL-2 expression
@en
Combination therapy with gossy ...... lls with high BCL-2 expression
@nl
type
label
Combination therapy with gossy ...... lls with high BCL-2 expression
@ast
Combination therapy with gossy ...... lls with high BCL-2 expression
@en
Combination therapy with gossy ...... lls with high BCL-2 expression
@nl
prefLabel
Combination therapy with gossy ...... lls with high BCL-2 expression
@ast
Combination therapy with gossy ...... lls with high BCL-2 expression
@en
Combination therapy with gossy ...... lls with high BCL-2 expression
@nl
P2093
P2860
P1433
P1476
Combination therapy with gossy ...... lls with high BCL-2 expression
@en
P2093
Foong Ying Wong
Fui Leng Yan
Lingzhi Wang
Natalia Liem
Wei-Peng Yong
Wing Cheong Wong
P2860
P304
P356
10.1371/JOURNAL.PONE.0050786
P407
P577
2012-01-01T00:00:00Z